U1 snRNP Aggregates Detection in Neurodegenerative Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases, such as Alzheimer's, lack effective tools for identifying early stages and specific protein aggregates, particularly those involving U1 small nuclear ribonucleoproteins (U1 snRNPs), which are key to understanding disease pathogenesis.
Innovation Solution
The method involves analyzing U1 snRNP components in brain tissue or cerebrospinal fluid samples for altered expression, using techniques like immunohistochemistry, mass spectrometry, and chromatography to detect U1-70K and other U1 snRNP proteins, and administering specific antibodies or antisense oligonucleotides to treat or prevent Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for neurodegenerative diseases, then diagnosis can be performed, but early stages and specific protein aggregates involving U1 snRNPs cannot be effectively identified
Solution Approach 1:
The patent introduces specific antibodies (e.g., anti-U1-70K antibodies) and detection reagents as intermediaries to bridge the gap between current diagnostic methods and the target protein aggregates. These intermediaries enable specific detection of U1 snRNP aggregates and other disease-related proteins that current methods cannot identify, thereby improving both measurement precision and diagnostic reliability
Solution Approach 2:
The patent employs multiple detection parameters including immunohistochemistry, mass spectrometry, and chromatography to analyze U1 snRNP components. By changing and combining multiple detection parameters, the patent achieves comprehensive identification of protein aggregates and altered expression patterns, resolving the limitation of current single-parameter diagnostic methods
2Loss of time
If U1 snRNP components are analyzed in brain tissue or CSF samples, then early diagnosis and treatment potential are enabled, but complex analytical techniques and sample manipulation are required
Solution Approach 1:
The patent performs preliminary actions by preparing specific antibodies, detection reagents, and control samples before actual diagnosis. Sample preprocessing steps including filtration to remove albumin and preparation of detergent-soluble and insoluble fractions are conducted in advance, enabling faster and more efficient early diagnosis while managing analytical complexity through systematic preparation
Solution Approach 2:
The patent segments the complex analysis into distinct modules: sample preparation, detergent solubility fractionation, immunodetection of specific proteins (U1-70K, U1A, etc.), and data interpretation. This segmentation allows each step to be optimized independently and facilitates early diagnosis by making the overall complex process more manageable and systematic
3Object-generated harmful factors
If specific antibodies or antisense oligonucleotides are administered to treat Alzheimer's, then potential treatment and prevention are achieved, but targeted delivery and specificity challenges arise
Solution Approach 1:
The patent uses antibodies and antisense oligonucleotides as intermediaries to deliver therapeutic effects. These biologics specifically bind to target proteins or RNA sequences involved in Alzheimer's pathogenesis, enabling targeted treatment while minimizing off-target effects. The intermediaries bridge the gap between administration and therapeutic action despite delivery challenges
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early diagnosis and potential treatment of Alzheimer's by identifying U1 snRNP aggregates and altering their expression, thereby addressing the underlying RNA splicing defects and amyloid precursor protein regulation.
Implementation Method 1
analyzing U1 snRNP components in brain tissue or cerebrospinal fluid samples for altered expression, using techniques like immunohistochemistry
Implementation Method 2
using techniques like immunohistochemistry, mass spectrometry, and chromatography to detect U1-70K and other U1 snRNP proteins
Implementation Method 3
using techniques like immunohistochemistry, mass spectrometry, and chromatography to detect U1-70K and other U1 snRNP proteins
Data Source
AI summary
This disclosure relates to methods of diagnosing neurodegenerative disease by analyzing proteins or protein expression profiles in a subject, or RNA or RNA expression profiles in a subject. In certain embodiments, the disclosure contemplates the diagnosis of preclinical or symptomatic stages of Alzheimer's disease, mild cognitive impairment, or chronic traumatic encephalopathy by identification of components of U1 small nuclear ribonucleoproteins or fragments thereof which are capable of forming cytoplasmic tangle-like structures.